AKS-452 is currently undergoing Phase II/III clinical testing in India as a primary vaccine; submission for Emergency Use Authorization (EUA) expected by Q3 2022
NextSWAB is currently optimized for nasal sample collection with validation for other sample types ongoing
CB03 is a candidate drug for the treatment of refractory epilepsy, independently developed by Zhimeng
Olumiant is the first and only JAK inhibitor USFDA-approved for the treatment of Covid-19
The company exports mobile surgery equipment to over 100 countries from Pune
“We are committed to making India a global medical value hub by further strengthening our traditional medicine industry and boosting 'Heal in India' & 'Heal by India'
Company's net income rose by 57.5 percent to 3.291 billion euros in Q1
ASC22 (Envafolimab) is a subcutaneously administered single-domain antibody against PD-L1 and has the potential to restore virus-specific immune responses in patients with chronic viral infection
The company intends to begin using drones to make deliveries of critical and emergency medical supplies, vaccines, and lifesaving drugs after getting the prerequisite regulatory approvals
The funding will enable the company to expand into the segment of HealthCare Service offerings, both in terms of geography and operations
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
